TOP TEN perturbations for Q9NVT9 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9NVT9
Selected probe(set): 222550_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9NVT9 (222550_at) across 5880 perturbations tested by GENEVESTIGATOR:

breast cancer study 3 / normal organelle sample

Relative Expression (log2-ratio):2.40596
Number of Samples:17 / 12
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal organelle sample
Normal organelle samples.

breast cancer study 4 / normal organelle sample

Relative Expression (log2-ratio):2.1462717
Number of Samples:4 / 12
Experimental breast cancer study 4
Breast BRCA1-deficient tumor samples.
Control normal organelle sample
Normal organelle samples.

breast cancer study 5 / normal organelle sample

Relative Expression (log2-ratio):2.0713034
Number of Samples:20 / 12
Experimental breast cancer study 5
Breast non-BLC (sporadic basal-like cancer) tumor samples.
Control normal organelle sample
Normal organelle samples.

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):2.0340137
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.0331974
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.9488478
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.9207306
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

rheumatoid arthritis study 31 / TNF-ɑ study 20

Relative Expression (log2-ratio):1.8772936
Number of Samples:4 / 3
Experimental rheumatoid arthritis study 31
Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocyte from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA.
Control TNF-ɑ study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocyte were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-1.8322954
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):1.7587814
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.